These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 33107564)

  • 1. The Impact of Intestinal Complications on Health Care Costs Among Patients With Inflammatory Bowel Disease Treated With Anti-Tumor Necrosis Factor Therapies.
    Rubin DT; Griffith J; Zhang Q; Hepp Z; Keshishian A
    Inflamm Bowel Dis; 2021 Jul; 27(8):1201-1209. PubMed ID: 33107564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends of Utilization of Tumor Necrosis Factor Antagonists in Children With Inflammatory Bowel Disease: A Canadian Population-Based Study.
    El-Matary W; Leung S; Tennakoon A; Benchimol EI; Bernstein CN; Targownik LE
    Inflamm Bowel Dis; 2020 Jan; 26(1):134-138. PubMed ID: 31323083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease.
    Dubinsky MC; Cross RK; Sandborn WJ; Long M; Song X; Shi N; Ding Y; Eichner S; Pappalardo B; Ganguli A; Wang A
    Inflamm Bowel Dis; 2018 Aug; 24(9):1876-1882. PubMed ID: 29668916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No Change in Surgical and Hospitalization Trends Despite Higher Exposure to Anti-Tumor Necrosis Factor in Inflammatory Bowel Disease in the Québec Provincial Database From 1996 to 2015.
    Verdon C; Reinglas J; Coulombe J; Gonczi L; Bessissow T; Afif W; Vutcovici M; Wild G; Seidman EG; Bitton A; Brassard P; Lakatos PL
    Inflamm Bowel Dis; 2021 Apr; 27(5):655-661. PubMed ID: 32676662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Earlier Anti-TNF Initiation Leads to Long-term Lower Health Care Utilization in Crohn's Disease but Not in Ulcerative Colitis.
    Targownik LE; Bernstein CN; Benchimol EI; Kaplan GG; Singh H; Tennakoon A; Nugent Z; Coward SB; Kuenzig ME; Murthy SK
    Clin Gastroenterol Hepatol; 2022 Nov; 20(11):2607-2618.e14. PubMed ID: 35247552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suboptimal response to tumor necrosis factor antagonists in inflammatory bowel disease in Latin America: EXPLORE LATAM study.
    Balderramo D; Yamamoto-Furusho J; Ponce de León E; de María J; Zubiaurre I; Pedreira S; Lis C; Brion L; de Paula JA
    Gastroenterol Hepatol; 2024 Jan; 47(1):51-62. PubMed ID: 37062500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rate of Adverse Events and Associated Health Care Costs for the Management of Inflammatory Bowel Disease in Germany.
    Wilke T; Groth A; Long GH; Tatro AR; Sun D
    Clin Ther; 2020 Jan; 42(1):130-143.e3. PubMed ID: 31883702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Anti-Tumor Necrosis Factor Therapy With Mortality Among Veterans With Inflammatory Bowel Disease.
    Cohen-Mekelburg S; Wallace BI; Van T; Wiitala WL; Govani SM; Burns J; Lipson R; Yun H; Hou J; Lewis JD; Dominitz JA; Waljee AK
    JAMA Netw Open; 2021 Mar; 4(3):e210313. PubMed ID: 33646314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healthcare resource utilization and treatment costs of Finnish chronic inflammatory bowel disease patients treated with infliximab
    Ylisaukko-Oja T; Torvinen S; Ventola H; Schmidt S; Herrala S; Kononoff J; Voutilainen M
    Scand J Gastroenterol; 2019 Jun; 54(6):726-732. PubMed ID: 31203693
    [No Abstract]   [Full Text] [Related]  

  • 10. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.
    Targownik LE; Benchimol EI; Bernstein CN; Singh H; Lix L; Tennakoon A; Leung S; Aviña A; Coward S; Jones J; Kaplan G; Murthy SK; Nguyen GC; Peña-Sánchez JN
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1788-1798.e2. PubMed ID: 30448599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from China with inflammatory bowel disease: results from the EXPLORE study.
    Li J; Liu Z; Hu P; Wen Z; Cao Q; Zou X; Chen Y; Wang Y; Zhong J; Shen X; Demuth D; Fadeeva O; Xie L; Chen J; Qian J
    BMC Gastroenterol; 2022 Feb; 22(1):44. PubMed ID: 35120446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of outcomes of continuation/discontinuation of 5-aminosalicylic acid after initiation of anti-tumor necrosis factor-alpha therapy in patients with inflammatory bowel disease.
    Choi YI; Kim TJ; Park DK; Chung JW; Kim KO; Kwon KA; Kim YJ
    Int J Colorectal Dis; 2019 Oct; 34(10):1713-1721. PubMed ID: 31471699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
    Burisch J
    Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009-2014.
    Kirchgesner J; Lemaitre M; Rudnichi A; Racine A; Zureik M; Carbonnel F; Dray-Spira R
    Aliment Pharmacol Ther; 2017 Jan; 45(1):37-49. PubMed ID: 27781286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study.
    Murthy SK; Begum J; Benchimol EI; Bernstein CN; Kaplan GG; McCurdy JD; Singh H; Targownik L; Taljaard M
    Gut; 2020 Feb; 69(2):274-282. PubMed ID: 31196874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammatory Bowel Disease Patients Who Respond to Treatment with Anti-tumor Necrosis Factor Agents Demonstrate Improvement in Pre-treatment Frailty.
    Kochar BD; Cai W; Ananthakrishnan AN
    Dig Dis Sci; 2022 Feb; 67(2):622-628. PubMed ID: 33932198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis.
    Billioud V; Ford AC; Tedesco ED; Colombel JF; Roblin X; Peyrin-Biroulet L
    J Crohns Colitis; 2013 Dec; 7(11):853-67. PubMed ID: 23523418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in Clinical Presentation of Eosinophilic Esophagitis in Pediatric Patients With Ulcerative Colitis and Crohn Disease.
    Splawski J; Aktay AN; Perry S; Baez-Socorro V; DeLozier S; Sferra TJ; Moses J
    J Pediatr Gastroenterol Nutr; 2022 Jul; 75(1):76-80. PubMed ID: 35442240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications.
    Targownik LE; Benchimol EI; Bernstein CN; Singh H; Tennakoon A; Zubieta AA; Coward S; Jones J; Kaplan GG; Kuenzig ME; Murthy SK; Nguyen GC; Peña-Sánchez JN
    J Crohns Colitis; 2020 Oct; 14(10):1354-1363. PubMed ID: 32648579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease.
    Lindsay JO; Armuzzi A; Gisbert JP; Bokemeyer B; Peyrin-Biroulet L; Nguyen GC; Smyth M; Patel H
    Dig Liver Dis; 2017 Oct; 49(10):1086-1091. PubMed ID: 28826571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.